EU ruling on $25 billion Abbott, St. Jude deal due by November 9
Traders gather at the booth that trades Abbott Laboratories on the floor of the New York Stock Exchange, December 10, 2012. REUTERS/Brendan McDermid/File Photo
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
BRUSSELS (Reuters) - EU antitrust regulators will decide by Nov. 9 whether to clear U.S. pharmaceuticals company Abbott Laboratories' (NYSE: ABT) $25-billion bid for St. Jude Medical Inc (NYSE: STJ) aimed at helping it better compete with bigger rivals.
Abbott sought the European Commission's approval for the deal on Oct. 3, according to a filing on the EU competition enforcer's website on Tuesday.
The Commission can either clear the deal with or without concessions or it can open a full-scale investigation if it has serious concerns. The majority of pharmaceutical mergers get the green light with or without conditions in the EU's preliminary review.
Abbott's takeover bid comes as medical equipment makers come under pressure to offer a wider portfolio of products to hospital customers, which have gained more negotiating power on pricing after a wave of mergers.
(Reporting by Foo Yun Chee; Editing by Mark Potter)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hyundai Motor executives to take voluntary 10 percent cut in wages
- Michigan court halts enforcement of law banning ballot 'selfies'
- U.S. takes aim at cyber attacks from connected devices as recalls mount
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!